Submitted:
05 January 2025
Posted:
07 January 2025
You are already at the latest version
Abstract
Application of liposomal drug delivery systems-a revolutionary approach applied in the modern therapeutic era-has shown great efficiency in elevating the level of efficacy and safety delivery drugs. Lipid-based vesicles enclose therapeutic agents with enhanced solubility, stability, and controlled release. Since their composition comprises both hydrophilic and hydrophobic drug components, it is possible for liposomes to encapsulate the latter as a way of overcoming some of the main challenges that come with the use of classical delivery systems. Some of the most significant clinical applications of liposomal formulations have been Doxil® for anticancer treatment and AmBisome® in fungal infections that significantly improved their pharmacokinetics and reduced toxicity. Liposomes have also served as very efficient carriers in delivering vaccines, where they were extremely useful in an mRNA vaccine formulation to elicit intense immune responses. The scope of liposomal systems for personalized medicine and targeted therapies is vast and keeps opening up the avenues of novel treatments to treat complex medical challenges. This paper is a review of the mechanism, advantages, clinical applications, and future prospects of liposomal drug delivery systems in modern therapeutics. Further highlighted with the development of new liposomal formulations and its inclusion with new technologies, it underlines the importance of liposomes in future drug delivery.
Keywords:
1. Introduction to Liposomes
1.1. Definition and Structure of Liposomes
1.2. Historical Context
1.3. Importance in Modern Medicine
2. Mechanisms of Liposomal Drug Delivery
2.1. Mechanisms of Action
2.1.1. Improved Solubility
2.1.2. Stability
2.1.3. Targeted Release
| S. No. | Mechanism | Description | References |
|---|---|---|---|
| 1 | Improved Solubility | Encapsulation enhances solubility of hydrophobic drugs and protects them from degradation. | [12] |
| 2 | Stability | Liposomes protect drugs from enzymatic degradation, ensuring effectiveness during circulation. | [13] |
| 3 | Targeted Release | Controlled release responds to stimuli, delivering drugs to target sites while reducing side effects. | [14] |
2.2. Advantages over Traditional Drug Delivery Methods
2.2.1. Reduced Toxicity
2.2.2. Enhanced Efficacy
2.2.3. Versatility
| S. No. | Advantage | Description | References |
|---|---|---|---|
| 1 | Reduced Toxicity | Targets drugs to specific tissues, reducing exposure to healthy cells and minimizing side effects. | [15] |
| 2 | Enhanced Efficacy | Improves solubility, stability, and bioavailability, allowing higher drug concentrations at target sites. | [16] |
| 3 | Versatility | Can carry various therapeutic agents (small molecules, proteins, nucleic acids) and be tailored for specific needs. | [17] |
2.3. Current Clinical Applications
2.3.1. Cancer Therapy
2.3.2. Infectious Diseases
2.3.3. Vaccine Delivery
| S. No. | Application | Description | Examples/References |
|---|---|---|---|
| 1 | Cancer Therapy | Liposomal doxorubicin (Doxil®) improves pharmacokinetics and reduces cardiotoxicity, treating cancers like breast cancer and Kaposi’s sarcoma. | Doxil® [18] |
| 2 | Infectious Diseases | Liposomal amphotericin B (AmBisome®) treats fungal infections with reduced nephrotoxicity and enhanced efficacy. | AmBisome® [19] |
| 3 | Vaccine Delivery | Liposomes act as adjuvants and delivery systems, improving vaccine stability and immune response, as seen in mRNA COVID-19 vaccines. | Liposomal Vaccines [20] |
3. Insights
3.1. Significance in Modern Therapeutics
3.1.1. Enhanced Drug Delivery
3.1.2. Targeted Therapy
3.1.3. Improved Stability
3.1.4. Versatility in Applications
3.1.5. Vaccine Delivery
3.2. Future Applications
3.2.1. Personalized Medicine [28]

3.2.2. Combination Therapies [29]

3.2.3. Gene Therapy [30]

3.2.4. Advanced Targeting Strategies [31,32,34,35]
![]() |
3.2.5. Regulatory and Commercialization Pathways [32,33,34,35]
![]() |
Conclusions
References
- Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. International Journal of Research Publication and Reviews, 4(8), 1379-1384. ISSN 2582-7421.
- Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. World Journal of Pharmaceutical Research, 13(13), 1155-1169.
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. World Journal of Pharmaceutical Research, 13(13), 1243-1262.
- Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. [CrossRef]
- Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World Journal of Pharmaceutical Research, 13(13), 1112-1140.
- Gabizon, A., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 42(5), 419-436. [CrossRef]
- Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. World Journal of Pharmaceutical Research, 13(16), 176-189.
- Reddy, L. H., & Reddy, S. M. (2011). Liposomal drug delivery systems: A review of their applications and potential. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Allen, T. M. (2002). Liposomes: Opportunities in drug delivery. Drugs of the Future, 27(1), 1-10.
- Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347.
- Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
- Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin: From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Torchilin, V. P. (2007). Micelles from lipid-core micelles to liposomes: A new approach to drug delivery. Drug Delivery, 14(1), 1-10.
- Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10.
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. [CrossRef]
- Sengar, A., Yadav, S., & Niranjan, S. K. (2024). Formulation and evaluation of mouth-dissolving films of Propranolol Hydrochloride. World Journal of Pharmaceutical Research, 13, 850–861.
- Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. World Journal of Pharmaceutical Research, 13(21), 1063–1071.
- Klibanov, A. L., & Maruyama, K. (2003). Liposomes for drug delivery: A review. Advanced Drug Delivery Reviews, 55(3), 329-347.
- Lasic, D. D. (1998). Liposomes: From physics to applications. In Liposomes: A Practical Approach (pp. 1-20). Oxford University Press.
- Gabizon, A., & Barenholz, Y. (2000). Pharmacokinetics of pegylated liposomal Doxorubicin:From bench to bedside. Clinical Pharmacokinetics, 39(2), 85-95. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Torchilin, V. P. (2007). Micelles from lipid-core micelles to liposomes: A new approach to drug delivery. Drug Delivery, 14(1), 1-10.
- Kato, Y., & Kato, Y. (2010). Liposomal drug delivery systems: A review of their applications in cancer therapy. Journal of Drug Delivery Science and Technology, 20(1), 1-10.
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Nature Reviews Drug Discovery, 9(12), 971-978. [CrossRef]
- Reddy, L. H., & Reddy, S. M. (2011). Liposomes: A review of their applications in drug delivery. Journal of Controlled Release, 153(1), 1-15. [CrossRef]
- Sengar, A., Tile, S. A., Sen, A., Malunjkar, S. P., Bhagat, D. T., & Thete, A. K. (2024, July 21). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. World Journal of Pharmaceutical Research, 13, 1424–1435.
- Sengar, A. (2024). Precision in practice: Nanotechnology and targeted therapies for personalized care. International Journal of Advanced Nano Computing and Analytics, 3(2), 56–67.
- Sengar, A. (2024, December 26). Liposomes and beyond: Pioneering vesicular systems for drug delivery. Preprint. Available online: https://www.preprints.org/manuscript/202412.2230/v1.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

